背景与目的:肿瘤的多药耐药(multidrug resistance,MDR)基因的表达是目前化疗失败的主要原因,磷脂酰肌醇-3-激酶(phosphoinositide 3-kinases,PI3K)信号通路参与肿瘤多药耐药的发生,但PI3K信号通路与多药耐药的机制尚不明确。本研究旨在探讨PI3K/Akt信号通路及其下游靶点对ATP结合蛋白亚家族1抗体(ATP-binding cassette sub-family B member 1,ABCB1)基因编码的P-糖蛋白(P-glycoprotein,P-gp)介导的人结肠癌耐奥沙利铂细胞株HCT-116/L-OHP细胞多药耐药性的调控作用。方法:将PI3K特异性抑制剂LY294002(20 μmol/L)处理人结肠癌HCT-116/L-OHP细胞2 h后,用细胞计数试剂盒-8(cell counting kit-8,CCK-8)检测细胞对奥沙利铂的敏感性;蛋白质印迹法(Western blot)检测相关耐药蛋白P-gp、肺耐药蛋白(lung resistance-related protein,LRP)、多药耐药相关蛋白-2(multidrug resistance-related-2,MRP-2)以及PI3K/Akt信号通路下游蛋白Akt、p-Akt、IκB、p-IκB的表达变化;CHIP—PCR法检测核转录因子κB(NF-κB)对ABCB1基因启动子的影响。结果:阻断PI3K/Akt信号通路激活后,奥沙利铂对HCT-116/L-OHP细胞的半数抑制浓度(IC50)由(157.48±16.73)μg/mL降至(53.68±3.18)μg/mL,逆转指数为2.93(P0.01)。HCT-116/L-OHP细胞的p-Akt、p-IκB和P-gp的表达水平明显下降(P0.01),Akt、IκB、LRP和MRP-2表达变化不明显。NF-κB能够与ABCB1基因启动子区域结合。结论:阻断PI3K/AKT信号通路可增强人结肠癌HCT-116/L-OHP耐药细胞的药物敏感性,抑制p-Akt和p-IκB的磷酸化表达水平,逆转P-gp介导的肠癌多药耐药。
Abstract
Background and purpose: Multidrug resistance (MDR) is the dominating obstacle to the chemotherapy. There is strong evidence that the phosphoinositide 3-kinases (PI3Ks) signaling pathway is involved in MDR phenotype
however
the mechanism of MDR occurrence is still unknown. This study tended to investigate the regulating effect of PI3K/Akt signaling pathway and its downstream target genes in P-glycoprotein (P-gp) (ABCB1 gene encoding)-mediated MDR in human colon carcinoma HCT-116/L-OHP cells. Methods: Pretreatment with PI3K selective inhibitor LY294002 (20 μmol/L) for 2 h
the sensitivity of L-OHP was evaluated by the CCK-8 (cell counting kit-8) assay in HCT-116/L-OHP cells
and the expressions of P-gp
LRP
MRP-2
Akt
p-Akt
IκB and p-IκB were evaluated by Western blot. The activity of ABCB1 promoter was evaluated by chromatin immunoprecipitation analysis (CHIP). Results: After inhibiting the activity of PI3K/Akt signaling pathway
the IC50 value of L-OHP decreased from(157.48±16.73) μg/mL to (53.68±3.18) μg/mL in HCT-116/L-OHP cells
and the reversal index was 2.93 (P0.01). The expressions of P-gp
p-Akt and p-IκB were down-regulation compared with the concrol group (P0.01)
but the expressions of LRP
MRP-2
Akt and IκB didn't change significantly. CHIP result has confirmed that NF-κB protein could bind to the region of ABCB1 gene promoter in HCT116/L-OHP cells. Conclusion: Blocking of PI3K/Akt/NF-kB signal pathway could increase the drug sensitivity to MDR cells
inhibit the phosphorylation of p-Akt and p-IκB
and reversing ABCB1/P-glycoprotein–mediated multidrug resistance in colon carcinoma cells.